The Effect of Estrogen Receptor Status on Survival in Breast Cancer Patients in Ethiopia. Retrospective Cohort Study

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. globocan iarc fr/Default aspx 2014; 2013.
   Google Scholar
• World Health Organization (2017). Cancer facts & figures 2016–2017. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed December 31, 2020.
   Google Scholar
• American Cancer Society. Breast Cancer Facts & Figures 2017–2018. Atlanta: American Cancer Society I; 2018.
   Google Scholar
• Lan N, Laohasiriwong W, Stewart J. Survival probability and prognostic factors for breast cancer patients in Vietnam. Glob Health Action. 2013;6(1):18860. doi:10.3402/gha.v6i0.18860
   PubMed Web of Science ®Google Scholar
• Ferlay J, Dikshit EM, Eser R, et al. Cancer incidence and mortality worldwide: IARC CancerBase; 2012:11.
   Google Scholar
• McKenzie F, Zietsman A, Galukande M, et al. African Breast Cancer—Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa. BMJ open. 2016;6(8):e011390. doi:10.1136/bmjopen-2016-011390
   PubMed Web of Science ®Google Scholar
• Abate S, Yilma Z, Assefa M, Tigeneh W. Trends of breast cancer in Ethiopia. Int J Cancer Res Mol Mech. 2016;2(1):1.
   Google Scholar
• Shiferaw WS, Aynalem YA, Akalu TY, Demelew TM. Incidence and predictors of recurrence among breast cancer patients in black lion specialized hospital adult oncology unit, Addis Ababa, Ethiopia: retrospective follow-up study with survival analysis. J Cancer Prev. 2020;25(2):111. doi:10.15430/JCP.2020.25.2.111
   PubMed Web of Science ®Google Scholar
• Walters S, Maringe C, Butler J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: a population-based study. Br J Cancer. 2013;108(5):1195–1208. doi:10.1038/bjc.2013.6
   PubMed Web of Science ®Google Scholar
• Kene TS, Odigie VI, Yusufu LM, Yusuf BO, Shehu SM, Kase JT. Pattern of presentation and survival of breast cancer in a teaching hospital in north Western Nigeria. Oman Med J. 2010;25(2):104. doi:10.5001/omj.2010.29
   PubMedGoogle Scholar
• Mensah AC, Yarney J, Nokoe SK, Opoku S, Clegg-Lamptey J. Survival outcomes of breast cancer in Ghana: an analysis of clinicopathological features. Open Access Library J. 2016;3:1–11.
   Google Scholar
• Kolarova I, Dusek L, Ryska A, et al. Impact of hormone receptor status on the behaviour of HER2+ breast cancer. In Vivo. 2020;34(6):3441–3449. doi:10.21873/invivo.12183
   PubMed Web of Science ®Google Scholar
• Group EBCTC. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8
   PubMed Web of Science ®Google Scholar
• Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218–228. doi:10.1093/jnci/djh025
   PubMed Web of Science ®Google Scholar
• Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):1–10. doi:10.1186/bcr1639
   Web of Science ®Google Scholar
• Jonasson JG, Stefansson OA, Johannsson OT, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer. 2016;115(7):776–783. doi:10.1038/bjc.2016.249
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Lynch HT, Foulkes WD, et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019;120(4):398–403. doi:10.1038/s41416-019-0376-y
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–8423. doi:10.1073/pnas.0932692100
   PubMed Web of Science ®Google Scholar
• Fisher B, Jeong J-H, Anderson S, Wolmark N. Treatment of axillary lymph node–negative, estrogen receptor–negative breast cancer: updated findings from national surgical adjuvant breast and bowel project clinical trials. J Natl Cancer Inst. 2004;96(24):1823–1831. doi:10.1093/jnci/djh338
   PubMedGoogle Scholar
• Sopik V, Sun P, Narod SA. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. Breast Cancer Res Treat. 2017;165(2):391–402. doi:10.1007/s10549-017-4333-2
   PubMed Web of Science ®Google Scholar
• Glück S, Russell C, O’Shaughnessy J, et al. Relationship between survival and estrogen receptor status in patients with metastatic breast cancer treated with capecitabine and docetaxel: an exploratory data analysis. In Poster presented at the 2009. ASCO Annual Meeting: 2009; 2009.
   Google Scholar
• Bloom H, Richardson W. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359. doi:10.1038/bjc.1957.43
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4
   PubMed Web of Science ®Google Scholar
• White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–399. doi:10.1002/sim.4067
   PubMed Web of Science ®Google Scholar
• Li Y, Yang D, Yin X, et al. Clinicopathological characteristics and breast cancer–specific survival of patients with single hormone receptor–positive breast cancer. JAMA network open. 2020;3(1):e1918160–e1918160. doi:10.1001/jamanetworkopen.2019.18160
   PubMed Web of Science ®Google Scholar
• Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Difference in Risk Factors for Breast Cancer by ER Status in an Indigenous African Population. International Scholarly Research Notices 2013; 2013.
   Google Scholar
• Zhao W, Sun L, Dong G, Wang X, Jia Y, Tong Z. Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer. Ther Adv Med Oncol. 2021;13:17588359211012982. doi:10.1177/17588359211012982
   Web of Science ®Google Scholar
• Ding Y, Ding K, Qian H, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre-and post-neoadjuvant chemotherapy in breast cancer. PLoS One. 2020;15(4):e0231895. doi:10.1371/journal.pone.0231895
   PubMed Web of Science ®Google Scholar